Global Premature Ovarian Failure Cure Market Growth (Status and Outlook) 2023-2029

Global Premature Ovarian Failure Cure Market Growth (Status and Outlook) 2023-2029

Premature ovarian failure (POF, also called primary ovarian insufficiency or early menopause) is a common gynecological endocrine disease characterized by the loss of ovarian function in women below 40 years. Most often, it is a non-reversible pathology leading to infertility. Normally, ovaries produce hormones and eggs until the early fifties, when they stop working and most women enter menopause. However, phenomena such as the dysfunction and the depletion of follicles (the cellular aggregates in the ovaries secreting hormones that influence the menstrual cycle) lead to POF, whose prevalence is 1/250 in women under 35 years and 1/100 in women under 40 years; the consequent loss of ovarian reserve (the number of follicles remaining in a woman’s ovaries) increases the risk of infertility, severely affecting women both physically and mentally.

LPI (LP Information)' newest research report, the “Premature Ovarian Failure Cure Industry Forecast” looks at past sales and reviews total world Premature Ovarian Failure Cure sales in 2022, providing a comprehensive analysis by region and market sector of projected Premature Ovarian Failure Cure sales for 2023 through 2029. With Premature Ovarian Failure Cure sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Premature Ovarian Failure Cure industry.

This Insight Report provides a comprehensive analysis of the global Premature Ovarian Failure Cure landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Premature Ovarian Failure Cure portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Premature Ovarian Failure Cure market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Premature Ovarian Failure Cure and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Premature Ovarian Failure Cure.

The global Premature Ovarian Failure Cure market size is projected to grow from US$ 855.8 million in 2022 to US$ 1457.7 million in 2029; it is expected to grow at a CAGR of 7.9% from 2023 to 2029.

Pfizer and Bayer are the top two manufacturers of premature ovarian failure cure globally and account for over 30% of global market share in total. Geographically speaking, North America holds about 45% of global market share, followed by Asia-Pacific with over 25% share. In terms of type, hormone replacement therapy (HRT) segment holds an important share of about 50%. In terms of application, 20 to 30 years old holds over 45% of total market share.

This report presents a comprehensive overview, market shares, and growth opportunities of Premature Ovarian Failure Cure market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Hormone Replacement Therapy (HRT)
Calcium and Vitamin D Supplements
In Vitro Fertilization (IVF)
Stem Cell Therapy
Others

Segmentation by application
Less than 20 Years Old
20 to 30 Years Old
30 to 45 Years Old
45 Years Old and Older

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Bayer
Novartis
Bioscience Institute
Johns Hopkins Medicine
Mayo Clinic
Baptist Health
Indira IVF

Please note: The report will take approximately 2 business days to prepare and deliver.